File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Conference Paper: Peripheral immunological response to treatment with checkpoint inhibitor in recurrent/metastatic nasopharyngeal carcinoma

TitlePeripheral immunological response to treatment with checkpoint inhibitor in recurrent/metastatic nasopharyngeal carcinoma
Authors
Issue Date2020
PublisherAmerican Society of Clinical Oncology. The Journal's web site is located at http://www.jco.org/
Citation
American Society of Clinical Oncology (ASCO) 56th Annual Meeting, Virtual meeting, Chicago, USA, 29 May - 02 June 2020. In Journal of Clinical Oncology, 2020, v. 38 n. 15, Suppl., abstract no. e18519 How to Cite?
AbstractBackground: A better understanding of peripheral cellular phenotypes in association with checkpoint inhibitors (CPI) responsiveness in recurrent/metastatic NPC could profoundly impact our knowledge of NPC immunopathology. Methods: Blood were collected from 11 patients with recurrent/metastatic NPC who received CPI (pembrolizumab) after failing second-line chemotherapy. Response to pembrolizumab was assessed by imaging and EBV DNA. Patients who achieved CR/PR were considered responsive and those with SD/PD were considered non-responsive. Four patients in the responsive group also had baseline blood before pembrolizumab. PBMC were freshly isolated and stored until analysis. For surface staining, cells were rested overnight at 37°C before resuspended in BD Brilliant stain with 2.5ng/µl Fc block for 15mins. Cells were then co-stained: 7-AAD, CD19-BV510, CD3-Alexa Fluo 700, CD4-BV510, CD279(PD-1)-BB515, CD197(CCR7)-BV421, CD45RO-APC, CD45RA-Pe-Cy5, CD8-APC-H7, CD27-PE, CD95-PE-Cy7, incubated on ice for 30mins. Samples were washed and acquired on NovoCyte Quanteon. Immune phenotypes were correlated with clinical response. Results: We found that: 1) %CD3 was upregulated in responsive group; 2) CD4/CD8 ratio did not directly stratify drug responsiveness; 3) frequency of PD1-expressing CD8+ T cells was significantly reduced in responsive group; 4) lower frequency of CCR7+PD1+CD8+ T cells in responsive group, suggesting that these may be highly differentiated and have the ability to move into peripheral sites in response to inflammatory chemokines; 5) frequency of naïve and TEMRA CD8+ T cells, but not Tscm was upregulated in responsive group; 6) finally, an interesting finding of sustained CD19+ subsets was observed in non-responsive group. Conclusions: Our results suggest that peripheral blood analysis may provide valuable insights into NPC patients’ responses to PD-1-targeted therapies.
DescriptionTrack:Head and Neck Cancer
Persistent Identifierhttp://hdl.handle.net/10722/290725
ISSN
2019 Impact Factor: 32.956
2015 SCImago Journal Rankings: 9.204

 

DC FieldValueLanguage
dc.contributor.authorKwong, DLW-
dc.contributor.authorKam, NW-
dc.contributor.authorLuk, HY-
dc.contributor.authorHung, TYD-
dc.contributor.authorYim, MK-
dc.contributor.authorLee, VHF-
dc.date.accessioned2020-11-02T05:46:14Z-
dc.date.available2020-11-02T05:46:14Z-
dc.date.issued2020-
dc.identifier.citationAmerican Society of Clinical Oncology (ASCO) 56th Annual Meeting, Virtual meeting, Chicago, USA, 29 May - 02 June 2020. In Journal of Clinical Oncology, 2020, v. 38 n. 15, Suppl., abstract no. e18519-
dc.identifier.issn0732-183X-
dc.identifier.urihttp://hdl.handle.net/10722/290725-
dc.descriptionTrack:Head and Neck Cancer-
dc.description.abstractBackground: A better understanding of peripheral cellular phenotypes in association with checkpoint inhibitors (CPI) responsiveness in recurrent/metastatic NPC could profoundly impact our knowledge of NPC immunopathology. Methods: Blood were collected from 11 patients with recurrent/metastatic NPC who received CPI (pembrolizumab) after failing second-line chemotherapy. Response to pembrolizumab was assessed by imaging and EBV DNA. Patients who achieved CR/PR were considered responsive and those with SD/PD were considered non-responsive. Four patients in the responsive group also had baseline blood before pembrolizumab. PBMC were freshly isolated and stored until analysis. For surface staining, cells were rested overnight at 37°C before resuspended in BD Brilliant stain with 2.5ng/µl Fc block for 15mins. Cells were then co-stained: 7-AAD, CD19-BV510, CD3-Alexa Fluo 700, CD4-BV510, CD279(PD-1)-BB515, CD197(CCR7)-BV421, CD45RO-APC, CD45RA-Pe-Cy5, CD8-APC-H7, CD27-PE, CD95-PE-Cy7, incubated on ice for 30mins. Samples were washed and acquired on NovoCyte Quanteon. Immune phenotypes were correlated with clinical response. Results: We found that: 1) %CD3 was upregulated in responsive group; 2) CD4/CD8 ratio did not directly stratify drug responsiveness; 3) frequency of PD1-expressing CD8+ T cells was significantly reduced in responsive group; 4) lower frequency of CCR7+PD1+CD8+ T cells in responsive group, suggesting that these may be highly differentiated and have the ability to move into peripheral sites in response to inflammatory chemokines; 5) frequency of naïve and TEMRA CD8+ T cells, but not Tscm was upregulated in responsive group; 6) finally, an interesting finding of sustained CD19+ subsets was observed in non-responsive group. Conclusions: Our results suggest that peripheral blood analysis may provide valuable insights into NPC patients’ responses to PD-1-targeted therapies.-
dc.languageeng-
dc.publisherAmerican Society of Clinical Oncology. The Journal's web site is located at http://www.jco.org/-
dc.relation.ispartofJournal of Clinical Oncology-
dc.relation.ispartof56th Annual Meeting of the American Society Of Clinical Oncology (ASCO 2020)-
dc.titlePeripheral immunological response to treatment with checkpoint inhibitor in recurrent/metastatic nasopharyngeal carcinoma-
dc.typeConference_Paper-
dc.identifier.emailKwong, DLW: dlwkwong@hku.hk-
dc.identifier.emailKam, NW: nwkam@hku.hk-
dc.identifier.emailHung, TYD: desmondh@hku.hk-
dc.identifier.emailYim, MK: paulyim@HKUCC-COM.hku.hk-
dc.identifier.emailLee, VHF: vhflee@hku.hk-
dc.identifier.authorityKwong, DLW=rp00414-
dc.identifier.authorityLee, VHF=rp00264-
dc.description.natureabstract-
dc.identifier.doi10.1200/JCO.2020.38.15_suppl.e18519-
dc.identifier.hkuros318596-
dc.identifier.volume38-
dc.identifier.issue15, Suppl.-
dc.identifier.spageabstract no. e18519-
dc.identifier.epageabstract no. e18519-
dc.publisher.placeUnited States-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats